AU2015292955B2 - Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same - Google Patents

Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same Download PDF

Info

Publication number
AU2015292955B2
AU2015292955B2 AU2015292955A AU2015292955A AU2015292955B2 AU 2015292955 B2 AU2015292955 B2 AU 2015292955B2 AU 2015292955 A AU2015292955 A AU 2015292955A AU 2015292955 A AU2015292955 A AU 2015292955A AU 2015292955 B2 AU2015292955 B2 AU 2015292955B2
Authority
AU
Australia
Prior art keywords
antibody
chain variable
variable region
cytosol
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015292955A
Other languages
English (en)
Other versions
AU2015292955A1 (en
Inventor
Dong Ki Choi
Sung Hoon Kim
Yong Sung Kim
Seung Min Shin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orum Therapeutics Inc
Original Assignee
Orum Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orum Therapeutics Inc filed Critical Orum Therapeutics Inc
Priority claimed from PCT/KR2015/007626 external-priority patent/WO2016013870A1/ko
Publication of AU2015292955A1 publication Critical patent/AU2015292955A1/en
Application granted granted Critical
Publication of AU2015292955B2 publication Critical patent/AU2015292955B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2015292955A 2014-07-22 2015-07-22 Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same Ceased AU2015292955B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2014-0092673 2014-07-22
KR20140092673 2014-07-22
KR1020150103163A KR101602870B1 (ko) 2014-07-22 2015-07-21 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
KR10-2015-0103163 2015-07-21
PCT/KR2015/007626 WO2016013870A1 (ko) 2014-07-22 2015-07-22 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용

Publications (2)

Publication Number Publication Date
AU2015292955A1 AU2015292955A1 (en) 2017-02-09
AU2015292955B2 true AU2015292955B2 (en) 2020-08-13

Family

ID=55354088

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015292955A Ceased AU2015292955B2 (en) 2014-07-22 2015-07-22 Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same

Country Status (11)

Country Link
US (1) US10844136B2 (enExample)
EP (1) EP3173428B1 (enExample)
JP (1) JP6595592B2 (enExample)
KR (1) KR101602870B1 (enExample)
CN (1) CN107001481A (enExample)
AU (1) AU2015292955B2 (enExample)
BR (1) BR112017001304A2 (enExample)
CA (1) CA2955272A1 (enExample)
IL (1) IL250203B (enExample)
RU (1) RU2017103675A (enExample)
ZA (1) ZA201700488B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9701740B2 (en) 2011-04-01 2017-07-11 Yale University Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
KR101602876B1 (ko) 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
MX2018014554A (es) 2016-05-27 2019-09-09 Orum Therapeutics Inc Anticuerpo penetrante de citosol y uso del mismo.
KR102000000B1 (ko) * 2016-05-27 2019-07-12 오름테라퓨틱 주식회사 항체에 엔도좀 탈출능을 부여하는 엔도좀 탈출 구조 모티프 및 이의 활용
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
EP3471777A1 (en) 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
EP3712180A4 (en) 2017-11-16 2021-08-11 Orum Therapeutics Inc. RAS INHIBITOR ANTIBODIES ACTIVATED IN A CELL BY INTERNALIZATION IN CYTOSOL OF THE CELL, AND ITS USE
WO2019152806A1 (en) * 2018-02-01 2019-08-08 Yale University Compositions and methods for enhancing nuclear translocation
JP7416433B2 (ja) * 2018-04-10 2024-01-17 ノースウェスタン ユニバーシティ 標的指向性親和性ドメインに基づく膜タンパク質を含む細胞外小胞
KR20190143826A (ko) * 2018-06-21 2019-12-31 오름테라퓨틱 주식회사 세포/조직 특이적 세포 침투 항체
WO2020022262A1 (en) * 2018-07-23 2020-01-30 Chugai Seiyaku Kabushiki Kaisha Target cell specific cytosol-penetrating antigen-binding molecules
CN110759996B (zh) * 2018-07-27 2022-09-06 深圳康体生命科技有限公司 一种gfp抗体
CN108949565B (zh) * 2018-09-26 2024-09-06 中国科学技术大学 用于红细胞负载冻干保护剂的装置及方法
WO2020221849A1 (en) * 2019-05-01 2020-11-05 Universidade De Santiago De Compostela Intracellular delivery of anti-kras antibodies formulated into nanocapsules
US20230076637A1 (en) 2020-02-06 2023-03-09 Ajou University Industry-Academic Cooperation Foundation Fusion antibody for presenting antigen-derived t cell antigen epitope or peptide containing same on cell surface, and composition comprising same
BR112022016643A2 (pt) * 2020-02-24 2022-10-11 Oblique Therapeutics Ab Epítopos e anticorpos contra kras
WO2021222333A1 (en) * 2020-04-30 2021-11-04 Genentech, Inc. Kras specific antibodies and uses thereof
US20240352100A1 (en) * 2021-07-20 2024-10-24 Ajou University Industry-Academic Cooperation Foundation Cell-penetrating degrading antibody that penetrates into cells to degrade and remove target protein and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134025A2 (ko) * 2008-04-29 2009-11-05 원우이에프엔지니어링 주식회사 열 및 연기 화재감지장치 복합시험기
WO2009134027A2 (en) * 2008-04-30 2009-11-05 Ajou University Industry-Academic Cooperation Foundation Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same
WO2010056043A2 (en) * 2008-11-11 2010-05-20 Ajou University Industry-Academic Cooperation Foundation Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2706486B1 (fr) 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
CN1241574A (zh) 1998-07-02 2000-01-19 中国人民解放军第四军医大学 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体
GB0226727D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intrabodies
AU2003219277A1 (en) 2002-03-14 2003-09-29 Medical Research Council Intracellular antibodies
JP2006521088A (ja) 2002-11-15 2006-09-21 メディカル リサーチ カウンシル 抗活性化ｒａｓ抗体
CN101448848B (zh) 2006-03-27 2013-12-04 全球免疫股份有限公司 Ras突变及其相关组合物和方法
GEP20156390B (en) 2008-01-03 2015-11-10 Scripps Research Inst Antibody targeting through a modular recognition domain
KR101075123B1 (ko) * 2008-10-24 2011-10-19 아주대학교산학협력단 핵산가수분해 능 및 암세포내 침투능력을 갖는 인간화된 항체 및 그 용도
CN101402675B (zh) 2008-11-28 2012-05-30 中国人民解放军第三军医大学第三附属医院 一种靶向抑制ανβ3阳性细胞增殖的环肽
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
GB201103631D0 (en) 2011-03-03 2011-04-13 Univ Leeds Identification of candidate therapeutics
US9701740B2 (en) 2011-04-01 2017-07-11 Yale University Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
US9815866B2 (en) 2012-09-14 2017-11-14 Japanese Foundation For Cancer Research Peptides that bind to epithelial cell adhesion molecule
US10011635B2 (en) 2013-09-27 2018-07-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
WO2016013871A1 (ko) 2014-07-22 2016-01-28 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
KR101602876B1 (ko) 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
KR102721595B1 (ko) 2015-04-03 2024-10-23 유레카 쎄라퓨틱스, 인코포레이티드 Afp 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도
KR101790669B1 (ko) 2015-10-14 2017-10-26 아주대학교산학협력단 개선된 분할 녹색 형광 단백질 상보 시스템 및 이의 용도
MX2018014554A (es) 2016-05-27 2019-09-09 Orum Therapeutics Inc Anticuerpo penetrante de citosol y uso del mismo.
KR101836392B1 (ko) 2016-08-17 2018-03-08 한림대학교 산학협력단 사이클릭 펩타이드를 포함하는 백신 조성물, 사이클릭 펩타이드에 대한 항체 또는 이를 포함하는 항암 조성물
EP3712180A4 (en) 2017-11-16 2021-08-11 Orum Therapeutics Inc. RAS INHIBITOR ANTIBODIES ACTIVATED IN A CELL BY INTERNALIZATION IN CYTOSOL OF THE CELL, AND ITS USE
KR20190143826A (ko) 2018-06-21 2019-12-31 오름테라퓨틱 주식회사 세포/조직 특이적 세포 침투 항체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134025A2 (ko) * 2008-04-29 2009-11-05 원우이에프엔지니어링 주식회사 열 및 연기 화재감지장치 복합시험기
WO2009134027A2 (en) * 2008-04-30 2009-11-05 Ajou University Industry-Academic Cooperation Foundation Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same
WO2010056043A2 (en) * 2008-11-11 2010-05-20 Ajou University Industry-Academic Cooperation Foundation Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
CA2955272A1 (en) 2016-01-28
AU2015292955A1 (en) 2017-02-09
KR101602870B1 (ko) 2016-03-21
US10844136B2 (en) 2020-11-24
JP6595592B2 (ja) 2019-10-23
KR20160011598A (ko) 2016-02-01
RU2017103675A (ru) 2018-08-06
JP2017529097A (ja) 2017-10-05
EP3173428A4 (en) 2018-01-24
ZA201700488B (en) 2018-12-19
BR112017001304A2 (pt) 2018-01-30
IL250203B (en) 2020-09-30
EP3173428B1 (en) 2020-02-19
CN107001481A (zh) 2017-08-01
US20170218084A1 (en) 2017-08-03
EP3173428A1 (en) 2017-05-31
IL250203A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
AU2015292955B2 (en) Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same
AU2015292956B2 (en) Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof
EP3275895B1 (en) Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof
AU2017271189B2 (en) Cytosol-penetrating antibody and use thereof
US10787487B2 (en) Cell/tissue-specific cell-penetrating antibodies
KR102091195B1 (ko) 세포질 침투 항체 및 이의 용도
CA3013584C (en) Antibody against egfrviii and use thereof
KR20180129514A (ko) 세포질 침투 항체 및 이의 용도
HK1240599A1 (en) Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same
HK1240492A1 (en) Method for suppressing ras activated in cell by using antibody having cytoplasm penetration capacity and complete immunoglobulin form, and use for same
EP3466970A1 (en) Cytosol-penetrating antibody and use thereof
KR20250093184A (ko) 고효율 세포질 침투 능을 갖는 세포질 침투 항체 및 이의 용도
NZ749020B2 (en) Cytosol-penetrating antibody and use thereof
HK40008311A (en) Cytosol-penetrating antibody and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired